44 -6 (56) 2023 — Yusupbekov A.A., Ismailova J.A. — GENETIC ASPECTS OF HELICOBACTER PYLORI IN GASTRIC DISEASES

GENETIC ASPECTS OF HELICOBACTER PYLORI IN GASTRIC DISEASES

Yusupbekov A.A., RSSPC of Oncology and Radiology

Ismailova J.A., RSSPC of Oncology and Radiology

Khakimov Ya., RSSPC of Therapy and Medical Rehabilitation

Muhiddinova N.Z. TSDI

Resume

The authors studied the epidemiological and molecular genetic characteristics of the bacterium in 279 patients with H. pylori-associated stomach diseases. The study is based on the results of endoscopic, molecular genetic research methods and statistical data. According to the study, the origin of various stomach diseases is closely related to the presence of the ureaC and CagA genes in H. pylori. In particular, in severe forms of stomach diseases, the frequency of occurrence of the CagA gene increased from 2.9 to 6.2 times. For this reason, the CagA gene can be considered as a biological marker gene for aggressive bacterial strains.

Keywords: H. rylori-associated diseases of the stomach, molecular genetic study, H. pylori, ureC and CagA genes.

First page

264

Last page

269

For citation: Yusupbekov A.A., Ismailova J.A., Khakimov Ya., Muhiddinova N.Z. – GENETIC ASPECTS OF HELICOBACTER PYLORI IN GASTRIC DISEASES //New Day in Medicine 2023 6(56): 264-269 https://newdaymedicine.com/index.php/2023/06/20/l-211/

LIST OF REFERENCES:

  1. Абдурахимов А.А. Гастриты, ассоциированные с Helicobacter pylori: Автореф. дисс. … канд. мед. наук. –Т., (2014):24.
  2. Бордин Д.С., Ливзан М. Консенсус Маастрихт VI опубликован: что нового? Эффективная фармакотерапия. (2022) 18(22):72-84.
  3. Исмаилова Ж.А., Юсупбеков А.А. Морфологические изменения слизистой оболочки при Нelicobacter рylori-ассоциированных заболеваниях желудка Терапевтический вестник Узбекистана, (2022) 4:127-132.
  4. Díaz P., Valenzuela Valderrama M., Bravo J., Quest A.F.G. Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression Front. Microbiol. (2018) 9(5).
  5. Fallone C.A., Chiba N., van Zanten S.V., Fischbach L., Gisbert J.P., Hunt R.H., et al. The toronto consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology (2016) 151:51-69. e14. doi: 10.1053/j.gastro.2016.04.006.
  6. Hong J., Shu X., Liu D., Zhu Y., Xie C., Xie Y., et al. Antibiotic resistance and CYP2C19 polymorphisms affect the efficacy of concomitant therapies for Helicobacter pylori infection: an open-label, randomized, single-centre clinical trial. J. Antimicrob. Chemother. (2016) 71:2280–2285. doi: 10.1093/jac/dkw118.
  7. Ismailova J.A., Yusupbekov A.A., Abdurahimov A.A. Results of the study of resistance to clarithromycin in patients with Helicobacter pylori-associated gastric diseases in Uzbekistan. Journal of Pharmaceutical Negative Results (2022) 13(6):3252-3259. Turkey.
  8. Malfertheiner P., Megraud F., O’morain C. et al., “Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report,” Gut, (2017) 66(1):6-30.
  9. Sugano K., Tack J., Kuipers E.J. et al. Kyoto global consensus report on Helicobacter pylori gastritis Gut. (2015) 64(9):1353-1367.
  10. Wald N.J. The treatment of Helicobacter pylori infection of the stomach in relation to the possible prevention of gastric cancer. In: IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer. Lyon, France: International Agency for Research on Cancer (IARC Working Group Reports, № 8); (2014):174-18.

file

download